Pretreatment Cytokine Signatures as Candidate Biomarkers for <scp>JAK</scp> Inhibitor Response in Anti‐ <scp>MDA5</scp> Dermatomyositis–Related Interstitial Lung Disease: A Pilot Study
Serum cytokine profiles may serve as prognostic markers in patients with MDA5+ DM-ILD treated with JAK inhibitors. The persistent elevation of multiple cytokines in nonsurvivors may reflect inadequate suppression of the cytokine storm despite treatment. Further research is needed to determine the optimal selection and timing of JAK inhibitor therapy.
Authors
- Hiroyuki Ide (ORCID: https://orcid.org/0000-0001-5120-4976)
- T. Koga
- Serina Koto
- Yuta Matsushita
- Takahisa Suzuki (ORCID: https://orcid.org/0000-0002-4940-4220)
- Momoko Okamoto
- Ayuko Takatani
- Haruna Matsuo
- Kanako Kojima
- Atsushi Kawakami
- Yuya Fujita
- Toshimasa Shimizu
Institutions
- Fukushima Medical University (JP)
- Japanese Red Cross Society, Japan (JP)
- Sasebo City General Hospital (JP)
- Japan Community Healthcare Organization (JP)
- Nagasaki University (JP)
Publication Details
- Journal
- ACR Open Rheumatology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/acr2.90002
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00